Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Immune Design Corp (IMDZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7993
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Immune Design’s product candidates are used for the treatment of NY-ESO-1 tumor antigen, merkel cell carcinoma, non-hodgkin lymphoma, and others. It has collaboration with various pharmaceutical companies, to develop its product candidates through its GLAAS platform for the treatment of infectious disease, allergy and autoimmune diseases. Immune Design is headquartered in Seattle, Washington, the US.

Immune Design Corp (IMDZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immune Design Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Immune Design Raises US$32.5 Million In Series C Financing 12
Immune Design Raises US$34 Million In Series B Financing 14
Partnerships 16
Immune Design Enters into Agreement with Gritstone Oncology 16
Immune Design Enters into Clinical Trial Collaboration with Genentech 17
Immune Design Enters into Clinical Collaboration Agreement with Merck 18
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 19
Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 20
Licensing Agreements 22
Sanofi Enters into Licensing Agreement with Immune Design 22
Immune Design Enters into Licensing Agreement with UNC Chapel Hill 23
Immune Design Licensing Agreement with Oxford BioMedica 24
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 25
Equity Offering 26
Immune Design Prices USD80 Million in Public Offering of Shares 26
Immune Design Prices Public Offering of Shares for USD30 Million 28
Immune design Plans to Raise up to USD50 Million in Public offering of Shares 30
Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 31
Immune Design Raises USD60 Million in IPO 33
Immune Design Corp – Key Competitors 35
Immune Design Corp – Key Employees 36
Immune Design Corp – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 01, 2018: Immune Design reports second quarter 2018 financial results and provides corporate update 38
Mar 14, 2018: Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 40
Nov 01, 2017: Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update 42
Aug 02, 2017: Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update 44
May 17, 2017: Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update 46
Mar 07, 2017: Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 48
Product News 50
09/25/2017: Immune Design Announces Upcoming Presentations at the SITC 32nd Annual Meeting 50
08/09/2018: Gritstone Oncology appoints experienced Financial Executive, Steve E. Krognes, to its Board of Directors 51
06/05/2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 52
06/01/2017: Immune responses from early study of novel sarcoma vaccine 54
05/17/2017: New Clinical and Biomarker Data Validate Immune Design’s CMB305 Program 56
Clinical Trials 58
May 24, 2018: Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma 58
Mar 12, 2018: Immune Design Reports Data Update for Lead Immunotherapy Program: Improvement in Survival for CMB305 Monotherapy in Sarcoma 59
Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients 60
Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response 61
Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress 63
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Immune Design Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immune Design Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immune Design Raises US$32.5 Million In Series C Financing 12
Immune Design Raises US$34 Million In Series B Financing 14
Immune Design Enters into Agreement with Gritstone Oncology 16
Immune Design Enters into Clinical Trial Collaboration with Genentech 17
Immune Design Enters into Clinical Collaboration Agreement with Merck 18
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 19
Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 20
Sanofi Enters into Licensing Agreement with Immune Design 22
Immune Design Enters into Licensing Agreement with UNC Chapel Hill 23
Immune Design Licensing Agreement with Oxford BioMedica 24
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 25
Immune Design Prices USD80 Million in Public Offering of Shares 26
Immune Design Prices Public Offering of Shares for USD30 Million 28
Immune design Plans to Raise up to USD50 Million in Public offering of Shares 30
Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 31
Immune Design Raises USD60 Million in IPO 33
Immune Design Corp, Key Competitors 35
Immune Design Corp, Key Employees 36
Immune Design Corp, Other Locations 37
Immune Design Corp, Subsidiaries 37

List of Figures
Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ProMIS Neurosciences Inc (PMN):製薬・医療:M&Aディール及び事業提携情報
    Summary ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of misfolded protein diseases. The company uses ProMIS technology, helps in pred …
  • Fulcrum Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company that focuses on the discovery and development of small molecule therapies to unlock the gene regulation in disease. The company’s pipeline products include Fragile X syndrome, Facioscapulohumeral muscular dystrophy …
  • FLYHT Aerospace Solutions Ltd.:企業の戦略・SWOT・財務分析
    FLYHT Aerospace Solutions Ltd. - Strategy, SWOT and Corporate Finance Report Summary FLYHT Aerospace Solutions Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • OncoSec Medical Inc (ONCS):医療機器:M&Aディール及び事業提携情報
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Nestle Health Science SA-医療機器分野:企業M&A・提携分析
    Summary Nestle Health Science SA (Nestle Health), a subsidiary of Nestle SA, is a health science company that manufactures nutritional and medicinal products derived from botanical plants. The company provides nutritional therapies for chronic conditions related to gastrointestinal diseases, aging p …
  • Electro Scientific Industries Inc (ESIO):企業の財務・戦略的SWOT分析
    Summary Electro Scientific Industries Inc (ESI) is a technology company that offers laser-based manufacturing solutions. The company offers products such as flex interconnect, circuit packaging, high density interconnect, automation, scribbing and grooving, memory repair, wafer marking, laser ablati …
  • Elia System Operator SA (ELI):電力:M&Aディール及び事業提携情報
    Summary Elia System Operator SA (Elia) is a transmission system operator. It owns and operates high-voltage electricity transmission systems in Belgium and Germany. The company transmits electricity from generators to distribution system operators and industrial consumers. Elia also imports and expo …
  • Flint Hills Resources LLC:企業の戦略的SWOT分析
    Flint Hills Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Shinsei Bank Ltd:企業のM&A・事業提携・投資動向
    Shinsei Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shinsei Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Arrowhead Pharmaceuticals Inc (ARWR):企業の財務・戦略的SWOT分析
    Summary Arrowhead Pharmaceuticals Inc (Arrowhead), formerly Arrowhead Research Corp, is a pharmaceutical company that develops and markets medicinal products. The company develops pipeline drugs that are being developed to treat chronic hepatitis B virus infection for the treatment of liver disease, …
  • Stena Metall AB:企業の戦略・SWOT・財務分析
    Stena Metall AB - Strategy, SWOT and Corporate Finance Report Summary Stena Metall AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Citibank Berhad:企業の戦略的SWOT分析
    Citibank Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Cleveland HeartLab Inc-医療機器分野:企業M&A・提携分析
    Summary Cleveland HeartLab Inc (Cleveland HeartLab) is a clinical laboratory that provides cardiovascular testing services. The company offers services such as cardiovascular risk assessment, novel diagnostic tests, inflammatory and other advanced biomarker testing, management and prevention of hear …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) operates as a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testoster …
  • Euro-Diagnostica AB:医療機器:M&Aディール及び事業提携情報
    Summary Euro-Diagnostica AB (Euro Diagnostica) is a medical device company that manufactures and markets purified antigens and antibodies. The company offers blood based solutions, developed to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune diseases. It offers product …
  • Primark Stores Ltd:企業の戦略・SWOT・財務分析
    Primark Stores Ltd - Strategy, SWOT and Corporate Finance Report Summary Primark Stores Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Eversource Energy:企業の発電所・SWOT分析2018
    Eversource Energy - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Lenenergo (LSNG):企業の財務・戦略的SWOT分析
    Lenenergo (LSNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Renata Ltd (RENATA):企業の財務・戦略的SWOT分析
    Summary Renata Ltd (Renata), formerly Pfizer Ltd, is a pharmaceutical and animal health product company. The company manufactures generic pharmaceutical products including hormones, contraceptives, anti cancer drugs, oral preparations, and other drugs. Its pharmaceutical product portfolio comprises …
  • Highmark Inc:企業の戦略的SWOT分析
    Highmark Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆